Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STK17B | O94768 | 1/20 | 0.46 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 5/20 | 0.41 |
| ▸ | DRD2 | P14416 | 5/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30522690 | 1.00 | STK17B (0.46) | STK17BSTK17ACA12CA1CA2 | |
| SCHEMBL24485105 | 0.86 | STK17B (0.47) | STK17BSTK17ACA12CA1CA2 | |
| SCHEMBL29828059 | 0.86 | KCNH2 (0.44) | STK17BSTK17ACA12CA1CA2 | |
| SCHEMBL24936244 | 0.86 | KCNH2 (0.44) | STK17BSTK17ACA12CA1CA2 | |
| SCHEMBL24936245 | 0.85 | STK17B (0.41) | STK17BSTK17ACA12CA1CA2 | |
| SCHEMBL30522714 | 0.83 | KCNH2 (0.50) | CA12CA1CA2CA9KCNH2 | |
| SCHEMBL24936189 | 0.83 | KCNH2 (0.50) | CA12CA1CA2CA9KCNH2 | |
| SCHEMBL29827348 | 0.79 | STK17B (0.41) | STK17BSTK17ACA12CA1CA2 | |
| SCHEMBL24936246 | 0.78 | KCNH2 (0.43) | STK17BSTK17ACA12CA1CA2 | |
| SCHEMBL24945078 | 0.77 | KCNH2 (0.51) | STK17BSTK17ACA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260022109-A1 | 5-HETEROARYL-1H-PYRAZOL-3-AMINE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2026-01-22 | — | — | US | disclosed |
| US-20250352541-A1 | THERAPEUTIC FOR CANCER REFRACTORY TO IMMUNE CHECKPOINT INHIBITOR | Sumitomo Pharma Co., Ltd. (JP) | 2025-11-20 | — | — | US | disclosed |
| US-12410154-B2 | 5-heteroaryl-1H-pyrazol-3-amine derivative | Sumitomo Pharma Co., Ltd. (JP) | 2025-09-09 | — | — | US | disclosed |
| EP-4534100-A1 | THERAPEUTIC FOR CANCER REFRACTORY TO IMMUNE CHECKPOINT INHIBITOR | Sumitomo Pharma Co., Ltd. (JP) | 2025-04-09 | — | — | EP | disclosed |
| WO-2023229032-A1 | THERAPEUTIC FOR CANCER REFRACTORY TO IMMUNE CHECKPOINT INHIBITOR | 住友ファーマ株式会社 | 2023-11-30 | — | — | WO | disclosed |
| EP-4253377-A1 | 5-HETEROARYL-1H-PYRAZOL-3-AMINE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2023-10-04 | — | — | EP | disclosed |
| CN-116546974-A | 5-heteroaryl-1H-pyrazol-3-amine derivatives | 住友制药株式会社 | 2023-08-04 | — | — | CN | disclosed |
| US-11564920-B2 | 5-heteroaryl-1H-pyrazol-3-amine derivative | Sumitomo Pharma Co., Ltd. (JP) | 2023-01-31 | — | — | US | disclosed |
| US-11564920-B2 | 5-heteroaryl-1H-pyrazol-3-amine derivative | Sumitomo Pharma Co., Ltd. (JP) | 2023-01-31 | — | — | US | disclosed |
| US-20230025065-A1 | 5-HETEROARYL-1H-PYRAZOL-3-AMINE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2023-01-26 | — | — | US | disclosed |
| US-20230025065-A1 | 5-HETEROARYL-1H-PYRAZOL-3-AMINE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2023-01-26 | — | — | US | disclosed |
| US-20220273649-A1 | 5-HETEROARYL-1H-PYRAZOL-3-AMINE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2022-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11564920-B2 | 5-heteroaryl-1H-pyrazol-3-amine derivative | CHEK1, CHEK2, RB1 | STK17B 529/4885STK17A 592/4885CA12 4344/4885 |
| US-20230025065-A1 | 5-HETEROARYL-1H-PYRAZOL-3-AMINE DERIVATIVE | CHEK1, CHEK2, RB1 | STK17B 529/4885STK17A 592/4885CA12 4344/4885 |
| US-20260022109-A1 | 5-HETEROARYL-1H-PYRAZOL-3-AMINE DERIVATIVE | CHEK1, CHEK2, WEE1 | STK17B 576/4885STK17A 507/4885CA12 3072/4885 |
| US-20220273649-A1 | 5-HETEROARYL-1H-PYRAZOL-3-AMINE DERIVATIVE | CHEK1, CHEK2, RB1 | STK17B 529/4885STK17A 592/4885CA12 4344/4885 |
| US-12410154-B2 | 5-heteroaryl-1H-pyrazol-3-amine derivative | CHEK1, CHEK2, RB1 | STK17B 529/4885STK17A 592/4885CA12 4344/4885 |
| US-20250352541-A1 | THERAPEUTIC FOR CANCER REFRACTORY TO IMMUNE CHECKPOINT INHIBITOR | CHEK1, CHEK2, PDCD1 | STK17B 691/4885STK17A 486/4885CA12 2526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.